Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|HER2/Neu Negative|Triple-Negative Breast Cancer
Interventions: DRUG: Talazoparib Tosylate
Sponsor: Melinda Telli
Collaborators: BioMarin Pharmaceutical|Pfizer